Verastem (VSTM) Long-Term Investments (2011 - 2021)

Verastem (VSTM) posted quarterly Long-Term Investments of $6.0 million for Q2 2021, little changed quarter-over-quarter from $6.0 million in Q1 2021.

Analysis

Verastem (VSTM) Long-Term Investments (2011 - 2021) Analysis & Trends

Verastem's Long-Term Investments history runs 7 years deep, the most recent figure standing at $6.0 million for Q2 2021.

In Q2 2021, Long-Term Investments changed N/A year-over-year to $6.0 million; the TTM figure through Jun 2021 stood at $6.0 million (changed N/A YoY), while the FY2020 annual figure was $6.0 million, changed N/A from the prior year.
Long-Term Investments for Q2 2021 stood at $6.0 million, roughly flat from $6.0 million in the prior quarter.
The five-year high for Long-Term Investments was $6.0 million in Q1 2021, with the low at $6.0 million in Q2 2021.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Investments (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn	5.79 Bn
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn	9.83 Bn
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn	-4.00 Mn
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn	1.77 Bn
5	Revolution Medicines	44.33 Bn	44.33 Bn	-	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn	-
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn	22.17 Mn
8	Royalty Pharma	28.45 Bn	27.61 Bn	-	372.10 Mn
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn	-
10	Verastem	814.94 Mn	678.59 Mn	36.32 Mn	-

Historic Data

Download Data